These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31762414)

  • 1. [Not Available].
    Rothe T
    Ther Umsch; 2019 Nov; 76(6):311-316. PubMed ID: 31762414
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Noninferiority Trial Comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study.
    Park SY; Kim S; Kim JH; Kim SH; Lee T; Yoon SY; Kim MH; Moon JY; Yang MS; Jung JW; Kim JH; Choi JH; Park CS; Kim S; Lee J; Kwon JW; Hur GY; Kim SH; Kim HK; Shin YS; Kim SH; Nam YH; Jang AS; Park SY; Kim TB;
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1304-1311.e2. PubMed ID: 33184024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
    Wilkie M; Finch S; Schembri S
    COPD; 2015; 12(5):582-90. PubMed ID: 25774769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
    Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
    COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy
    Cazzola M; Rogliani P; Calzetta L; Matera MG
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30309975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Asthma and COPD: guidance in the jungle of inhalative drugs].
    Hering T
    MMW Fortschr Med; 2015 May; 157(10):59, 61-2. PubMed ID: 26019099
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
    Ding B; Small M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis.
    Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T
    Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple inhaled therapy for chronic obstructive pulmonary disease.
    Montuschi P; Malerba M; Macis G; Mores N; Santini G
    Drug Discov Today; 2016 Nov; 21(11):1820-1827. PubMed ID: 27452453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.